Literature DB >> 2513720

Increased placental progesterone may cause decreased placental prostacyclin production in preeclampsia.

S W Walsh1, S Coulter.   

Abstract

UNLABELLED: Placentas obtained from women with preeclampsia produce more thromboxane and less prostacyclin than normal. They also produce more progesterone than normal. This study tested whether a progesterone concentration equivalent to that in the medium after in vitro incubation of placentas from women with preeclampsia (greater than or equal to 1.5 x 10(-5) mol/L) could cause an imbalance of increased thromboxane and decreased prostacyclin production by normal placentas. Fresh term placental tissues were incubated for 48 hours in the absence or presence of various concentrations of progesterone and/or estradiol. Prostacyclin and thromboxane were determined by radioimmunoassay of their stable metabolites, 6-keto-prostaglandin F1 alpha and thromboxane B2. A progesterone concentration of 1.5 x 10(-5) mol/L significantly (p less than 0.001) inhibited prostacyclin production, compared with control, but lower concentrations did not. Estradiol at concentrations present in the medium after incubation of either normal or preeclamptic placental tissue did not significantly affect prostacyclin production, nor did it prevent progesterone at 1.5 x 10(-5) mol/L from inhibiting prostacyclin. Thromboxane production was not affected by either progesterone or estradiol.
CONCLUSION: In vitro addition of progesterone at a concentration equivalent to that in the medium after incubation of preeclamptic placentas inhibited prostacyclin production by normal placentas to a rate characteristic of preeclampsia. However, it did not increase thromboxane. SPECULATION: Increased trophoblast progesterone in preeclampsia may act by a paracrine mechanism to inhibit prostacyclin synthesis in placental vasculature. Progesterone's selective inhibition of prostacyclin without affecting thromboxane may be due to the compartmentalization of thromboxane production to trophoblast and stroma and prostacyclin production to placental vasculature.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2513720     DOI: 10.1016/0002-9378(89)90931-9

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  4 in total

1.  A Proposed Molecular Mechanism of High-Dose Vitamin D3 Supplementation in Prevention and Treatment of Preeclampsia.

Authors:  Piotr Zabul; Michal Wozniak; Andrzej T Slominski; Krzysztof Preis; Magdalena Gorska; Marek Korozan; Jan Wieruszewski; Michal A Zmijewski; Ewa Zabul; Robert Tuckey; Alicja Kuban-Jankowska; Wieslawa Mickiewicz; Narcyz Knap
Journal:  Int J Mol Sci       Date:  2015-06-09       Impact factor: 5.923

Review 2.  Could Vitamin D Be Effective in Prevention of Preeclampsia?

Authors:  Elżbieta Poniedziałek-Czajkowska; Radzisław Mierzyński
Journal:  Nutrients       Date:  2021-10-28       Impact factor: 5.717

3.  A comprehensive analysis of metabolomics and transcriptomics to reveal major metabolic pathways and potential biomarkers of human preeclampsia placenta.

Authors:  Yan Feng; Xinlei Lian; Kaimin Guo; Guanglan Zhang; Xuan Huang
Journal:  Front Genet       Date:  2022-10-03       Impact factor: 4.772

Review 4.  Sex Steroids Modulate Uterine-Placental Vasculature: Implications for Obstetrics and Neonatal Outcomes.

Authors:  Manuel Maliqueo; Bárbara Echiburú; Nicolás Crisosto
Journal:  Front Physiol       Date:  2016-04-26       Impact factor: 4.566

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.